What question did this study set out to answer?

To determine the efficacy, tolerability, and safety of the novel topical macrolactam SDZ ASM 981 in chronic plaque-type psoriasis.

December 1, 1998British Journal of Dermatology

The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion

View Full Paper

Ask AI

Bookmark

Authors

MMrowietzFachhochschule Kiel GGraeber BBRÄutigam

Discussion

Member takes

Overview

Randomized double-blind trial demonstrates topical SDZ ASM 981 reduces clinical symptom scores in plaque psoriasis, indicating strong therapeutic efficacy under occlusion.

Key Points

To determine the efficacy, tolerability, and safety of the novel topical macrolactam SDZ ASM 981 in chronic plaque-type psoriasis.
Conducted a randomized, double-blind, within-subject comparison in 10 patients with chronic plaque-type psoriasis for 2 weeks using the microplaque assay under occlusion.
Tested SDZ ASM 981 (0.3% and 1.0%), placebo ointment base, and open-label clobetasol-17-propionate ointment (0.05%), monitoring daily clinical scores for erythema and induration.
Total clinical scores decreased by 82% with 1.0% SDZ ASM 981 and by 63% with 0.3% SDZ ASM 981, compared to an 18% reduction with placebo ointment base and a 92% reduction with 0.05% clobetasol-17-propionate.
No adverse drug effects were observed in any patient during the study period.

Cite This Study

Mrowietz et al. (1998) studied this question.

synapsesocial.com/papers/6a7bb723073f483584df888c https://doi.org/10.1046/j.1365-2133.1998.02554.x

View Full Paper

Ask AI

Bookmark

December 1, 1998British Journal of Dermatology

The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion

View Full Paper

Ask AI

Bookmark

Authors

MMrowietzFachhochschule Kiel GGraeber BBRÄutigam

Discussion

Member takes

Overview

Randomized double-blind trial demonstrates topical SDZ ASM 981 reduces clinical symptom scores in plaque psoriasis, indicating strong therapeutic efficacy under occlusion.

Key Points

To determine the efficacy, tolerability, and safety of the novel topical macrolactam SDZ ASM 981 in chronic plaque-type psoriasis.
Conducted a randomized, double-blind, within-subject comparison in 10 patients with chronic plaque-type psoriasis for 2 weeks using the microplaque assay under occlusion.
Tested SDZ ASM 981 (0.3% and 1.0%), placebo ointment base, and open-label clobetasol-17-propionate ointment (0.05%), monitoring daily clinical scores for erythema and induration.
Total clinical scores decreased by 82% with 1.0% SDZ ASM 981 and by 63% with 0.3% SDZ ASM 981, compared to an 18% reduction with placebo ointment base and a 92% reduction with 0.05% clobetasol-17-propionate.
No adverse drug effects were observed in any patient during the study period.

Cite This Study

Mrowietz et al. (1998) studied this question.

synapsesocial.com/papers/6a7bb723073f483584df888c https://doi.org/10.1046/j.1365-2133.1998.02554.x

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark